Role of the mTOR signaling pathway in epilepsy

Journal of the Neurological Sciences

Volumn 332, Issue 1-2, 2013, Pages 4-15

  Meng, Xiang Fei ^a   Yu, Jin Tai ^a,b,c   Song, Jing Hui ^d   Chi, Song ^d   Tan, Lan ^a,b,c  

^a QINGDAO UNIVERSITY   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Epilepsy; Epileptogenesis; Focal cortical dysplasias; mTOR; Rapamycin; Seizure; Therapy; Tuberous sclerosis complex

Indexed keywords

CURCUMIN; EVEROLIMUS; KAINIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PILOCARPINE; PROTEIN S6; RAPAMYCIN; RESVERATROL; RIDAFOROLIMUS; TEMSIROLIMUS;

CORTICAL DYSPLASIA; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; INFANTILE SPASM; KETOGENIC DIET; LEUKOPENIA; LOW CARBOHYDRATE DIET; MOUTH INFECTION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RESPIRATORY TRACT INFECTION; REVIEW; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TRAUMATIC BRAIN INJURY;

EPILEPSY; EPILEPTOGENESIS; FOCAL CORTICAL DYSPLASIAS; MTOR; RAPAMYCIN; SEIZURE; THERAPY; TUBEROUS SCLEROSIS COMPLEX;

ANIMALS; BRAIN; EPILEPSY; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84881474333     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.05.029     Document Type: Review

References (142)

1. K.A. Orlova, and P.B. Crino The tuberous sclerosis complex Ann N Y Acad Sci 1184 2010 87 105
2. L.H. Zeng, N.R. Rensing, and M. Wong The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy J Neurosci 29 2009 6964 6972
3. E. Raffo, A. Coppola, T. Ono, S.W. Briggs, and A.S. Galanopoulou A pulse rapamycin therapy for infantile spasms and associated cognitive decline Neurobiol Dis 43 2011 322 329
4. C.J. Sabers, M.M. Martin, G.J. Brunn, J.M. Williams, F.J. Dumont, and G. Wiederrecht Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells J Biol Chem 270 1995 815 822
5. C.H. Cho Frontier of epilepsy research - mTOR signaling pathway Exp Mol Med 43 2011 231 274
6. J.D. Weber, and D.H. Gutmann Deconvoluting mTOR biology Cell Cycle 11 2012 236 248
7. C.M. Hung, L. Garcia-Haro, C.A. Sparks, and D.A. Guertin mTOR-dependent cell survival mechanisms Cold Spring Harb Perspect Biol 4 2012
8. Z. Yang, and X.F. Ming mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases Obes Rev 13 Suppl. 2 2012 58 68
9. J.L. Jewell, R.C. Russell, and K.L. Guan Amino acid signalling upstream of mTOR Nat Rev Mol Cell Biol 14 2013 133 139
10. N. Tapon, N. Ito, B.J. Dickson, J.E. Treisman, and I.K. Hariharan The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation Cell 105 2001 345 355
11. X. Gao, and D. Pan TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth Genes Dev 15 2001 1383 1392
12. S.L. Dabora, S. Jozwiak, D.N. Franz, P.S. Roberts, A. Nieto, and J. Chung Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs Am J Hum Genet 68 2001 64 80
13. L.H. Zeng, N.R. Rensing, B. Zhang, D.H. Gutmann, M.J. Gambello, and M. Wong Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex Hum Mol Genet 20 2011 445 454
14. Y. Wang, M.F. Barbaro, and S.C. Baraban A role for the mTOR pathway in surface expression of AMPA receptors Neurosci Lett 401 2006 35 39
15. K.F. Raab-Graham, P.C. Haddick, Y.N. Jan, and L.Y. Jan Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites Science 314 2006 144 148
16. C.A. Hoeffer, and E. Klann mTOR signaling: at the crossroads of plasticity, memory and disease Trends Neurosci 33 2010 67 75
17. S.J. Tang, G. Reis, H. Kang, A.C. Gingras, N. Sonenberg, and E.M. Schuman A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus Proc Natl Acad Sci U S A 99 2002 467 472
18. R. Gong, C.S. Park, N.R. Abbassi, and S.J. Tang Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons J Biol Chem 281 2006 18802 18815
19. J. Jaworski, and M. Sheng The growing role of mTOR in neuronal development and plasticity Mol Neurobiol 34 2006 205 219
20. G.M. Schratt, E.A. Nigh, W.G. Chen, L. Hu, and M.E. Greenberg BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development J Neurosci 24 2004 7366 7377
21. C.C. Lee, C.C. Huang, M.Y. Wu, and K.S. Hsu Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway J Biol Chem 280 2005 18543 18550
22. D.S. Campbell, and C.E. Holt Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation Neuron 32 2001 1013 1026
23. D. Nie, A. Di Nardo, J.M. Han, H. Baharanyi, I. Kramvis, and T. Huynh Tsc2-Rheb signaling regulates EphA-mediated axon guidance Nat Neurosci 13 2010 163 172
24. J. Jaworski, S. Spangler, D.P. Seeburg, C.C. Hoogenraad, and M. Sheng Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt- mammalian target of rapamycin pathway J Neurosci 25 2005 11300 11312
25. L. Swiech, M. Perycz, A. Malik, and J. Jaworski Role of mTOR in physiology and pathology of the nervous system Biochim Biophys Acta 1784 2008 116 132
26. J. Roa, D. Garcia-Galiano, L. Varela, M.A. Sanchez-Garrido, R. Pineda, and J.M. Castellano The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system Endocrinology 150 2009 5016 5026
27. J.T. Smith Sex steroid control of hypothalamic Kiss1 expression in sheep and rodents: comparative aspects Peptides 30 2009 94 102
28. H. Mori, K. Inoki, H. Munzberg, D. Opland, M. Faouzi, and E.C. Villanueva Critical role for hypothalamic mTOR activity in energy balance Cell Metab 9 2009 362 374
29. R. Cao, A. Li, H.Y. Cho, B. Lee, and K. Obrietan Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock J Neurosci 30 2010 6302 6314
30. W. Balduini, S. Carloni, and G. Buonocore Autophagy in hypoxia-ischemia induced brain injury J Matern Fetal Neonatal Med 25 Suppl. 1 2012 30 34
31. G.D. Shi, Y.P. OuYang, J.G. Shi, Y. Liu, W. Yuan, and L.S. Jia PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway Biochem Biophys Res Commun 404 2011 941 945
32. W. Zhang, N.H. Khatibi, M. Yamaguchi-Okada, J. Yan, C. Chen, and Q. Hu Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines Exp Neurol 233 2012 799 806
33. A. Sekiguchi, H. Kanno, H. Ozawa, S. Yamaya, and E. Itoi Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice J Neurotrauma 29 2012 946 956
34. Y.C. Shang, Z.Z. Chong, S. Wang, and K. Maiese Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia Curr Neurovasc Res 8 2011 270 285
35. B. Sheng, J. Liu, and G.H. Li Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling Comp Biochem Physiol B Biochem Mol Biol 163 2012 51 58
36. G. Liu, M.R. Detloff, K.N. Miller, L. Santi, and J.D. Houle Exercise modulates microRNAs that affect the PTEN/mTOR pathway in rats after spinal cord injury Exp Neurol 233 2012 447 456
37. F. Sun, K.K. Park, S. Belin, D. Wang, T. Lu, and G. Chen Sustained axon regeneration induced by co-deletion of PTEN and SOCS3 Nature 480 2011 372 375
38. C.L. Walker, M.J. Walker, N.K. Liu, E.C. Risberg, X. Gao, and J. Chen Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury PLoS One 7 2012 e30012
39. D.R. Plas, and G. Thomas Tubers and tumors: rapamycin therapy for benign and malignant tumors Curr Opin Cell Biol 21 2009 230 236
40. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, and P. Mangeshkar Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
41. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, and R. Kuperman Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 2013 125 132
42. K. Kotulska, D. Chmielewski, J. Borkowska, E. Jurkiewicz, D. Kuczynski, and T. Kmiec Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex Eur J Paediatr Neurol 2013 10.1016/j.ejpn.2013. 03.002 (in press)
43. V.P. Krymskaya, and E.A. Goncharova PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects Cell Cycle 8 2009 403 413
44. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644
45. M.E. Feldman, B. Apsel, A. Uotila, R. Loewith, Z.A. Knight, and D. Ruggero Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol 7 2009 e38
46. C.C. Thoreen, S.A. Kang, J.W. Chang, Q. Liu, J. Zhang, and Y. Gao An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J Biol Chem 284 2009 8023 8032
47. J.M. Freeman, and E.H. Kossoff Ketosis and the ketogenic diet, 2010: advances in treating epilepsy and other disorders Adv Pediatr 57 2010 315 329
48. S.S. McDaniel, N.R. Rensing, L.L. Thio, K.A. Yamada, and M. Wong The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway Epilepsia 52 2011 e7 e11
49. C.S. Beevers, L. Chen, L. Liu, Y. Luo, N.J. Webster, and S. Huang Curcumin disrupts the Mammalian target of rapamycin-raptor complex Cancer Res 69 2009 1000 1008
50. A. Jyoti, P. Sethi, and D. Sharma Curcumin protects against electrobehavioral progression of seizures in the iron-induced experimental model of epileptogenesis Epilepsy Behav 14 2009 300 308
51. B. Dasgupta, and J. Milbrandt Resveratrol stimulates AMP kinase activity in neurons Proc Natl Acad Sci U S A 104 2007 7217 7222
52. S. Frojdo, D. Cozzone, H. Vidal, and L. Pirola Resveratrol is a class IA phosphoinositide 3-kinase inhibitor Biochem J 406 2007 511 518
53. M. Liu, S.A. Wilk, A. Wang, L. Zhou, R.H. Wang, and W. Ogawa Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR J Biol Chem 285 2010 36387 36394
54. T. Chachua, K.L. Poon, M.S. Yum, L. Nesheiwat, K. DeSantis, and J. Veliskova Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats Epilepsia 53 2012 2015 2025
55. K. Araki, A.P. Turner, V.O. Shaffer, S. Gangappa, S.A. Keller, and M.F. Bachmann mTOR regulates memory CD8 T-cell differentiation Nature 460 2009 108 112
56. F.X. McCormack, Y. Inoue, J. Moss, L.G. Singer, C. Strange, and K. Nakata Efficacy and safety of sirolimus in lymphangioleiomyomatosis N Engl J Med 364 2011 1595 1606
57. J. Zuber, D. Anglicheau, C. Elie, L. Bererhi, M.O. Timsit, and M.F. Mamzer-Bruneel Sirolimus may reduce fertility in male renal transplant recipients Am J Transplant 8 2008 1471 1479
58. J.E. Wilkinson, L. Burmeister, S.V. Brooks, C.C. Chan, S. Friedline, and D.E. Harrison Rapamycin slows aging in mice Aging Cell 11 2012 675 682
59. E. Gyurus, Z. Kaposztas, and B.D. Kahan Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens Transplant Proc 43 2011 1583 1592
60. E. Lopez, A. Berna-Erro, N. Bermejo, J.M. Brull, R. Martinez, and G. Garcia Pino Long-term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients J Cell Mol Med 17 2013 636 647
61. A.M. Turpeinen, S. Jarvenpaa, H. Kautiainen, R. Korpela, and H. Vapaatalo Antihypertensive effects of bioactive tripeptides - a random effects meta-analysis Ann Med 45 2013 51 56
62. X. Lv, X. Ma, and Y. Hu Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment Expert Opin Drug Discovery 2013 10.1517/17460441.2013.800479 (in press)
63. M. van Slegtenhorst, R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, and S. Verhoef Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 Science 277 1997 805 808
64. R.S. Kandt, J.L. Haines, M. Smith, H. Northrup, R.J. Gardner, and M.P. Short Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease Nat Genet 2 1992 37 41
65. M. van Slegtenhorst, M. Nellist, B. Nagelkerken, J. Cheadle, R. Snell, and A. van den Ouweland Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products Hum Mol Genet 7 1998 1053 1057
66. R.P. Carson, C. Fu, P. Winzenburger, and K.C. Ess Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex Hum Mol Genet 22 2013 140 152
67. P.B. Crino, J.Q. Trojanowski, M.A. Dichter, and J. Eberwine Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology Proc Natl Acad Sci U S A 93 1996 14152 14157
68. H.J. Baskin Jr. The pathogenesis and imaging of the tuberous sclerosis complex Pediatr Radiol 38 2008 936 952
69. M. Wong Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation Epilepsia 49 2008 8 21
70. S. Koh, P. Jayakar, C. Dunoyer, S.E. Whiting, T.J. Resnick, and L.A. Alvarez Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome Epilepsia 41 2000 1206 1213
71. F.E. Jansen, A.C. van Huffelen, A. Algra, and O. van Nieuwenhuizen Epilepsy surgery in tuberous sclerosis: a systematic review Epilepsia 48 2007 1477 1484
72. G.L. Holmes, and C.E. Stafstrom Tuberous sclerosis complex and epilepsy: recent developments and future challenges Epilepsia 48 2007 617 630
73. P. Major, S. Rakowski, M.V. Simon, M.L. Cheng, E. Eskandar, and J. Baron Are cortical tubers epileptogenic? Evidence from electrocorticography Epilepsia 50 2009 147 154
74. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann Neurol 63 2008 444 453
75. L. Meikle, K. Pollizzi, A. Egnor, I. Kramvis, H. Lane, and M. Sahin Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function J Neurosci 28 2008 5422 5432
76. D. Ehninger From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches Neuropharmacology 68 2013 97 105
77. +/- mouse model of tuberous sclerosis Nat Med 14 2008 843 848
78. D.N. Franz Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis Expert Rev Anticancer Ther 11 2011 1181 1192
79. J. Muncy, I.J. Butler, and M.K. Koenig Rapamycin reduces seizure frequency in tuberous sclerosis complex J Child Neurol 24 2009 477
80. B. Zhang, S.S. McDaniel, N.R. Rensing, and M. Wong Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex PLoS One 8 2013 e57445
81. S. Jozwiak, R. Nabbout, and P. Curatolo Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations Eur J Paediatr Neurol 2013 10.1016/j.ejpn.2012.12.008 (in press)
82. S. Anderl, M. Freeland, D.J. Kwiatkowski, and J. Goto Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex Hum Mol Genet 20 2011 4597 4604
83. X.R. Ortiz-Gonzalez, A. Poduri, C.M. Roberts, J.E. Sullivan, E.D. Marsh, and B.E. Porter Focal cortical dysplasia is more common in boys than in girls Epilepsy Behav 27 2013 121 123
84. I. Blumcke, M. Thom, E. Aronica, D.D. Armstrong, H.V. Vinters, and A. Palmini The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission Epilepsia 52 2011 158 174
85. M. Baybis, J. Yu, A. Lee, J.A. Golden, H. Weiner, and G. McKhann II mTOR cascade activation distinguishes tubers from focal cortical dysplasia Ann Neurol 56 2004 478 487
86. V. Schick, M. Majores, G. Engels, W. Hartmann, C.E. Elger, and J. Schramm Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells Brain Pathol 17 2007 165 173
87. M.C. Ljungberg, M.B. Bhattacharjee, Y. Lu, D.L. Armstrong, D. Yoshor, and J.W. Swann Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia Ann Neurol 60 2006 420 429
88. P.B. Crino Focal brain malformations: a spectrum of disorders along the mTOR cascade Novartis Found Symp 288 2007 260 272 [discussion 72-81]
89. J. Zhou, J. Blundell, S. Ogawa, C.H. Kwon, W. Zhang, and C. Sinton Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice J Neurosci 29 2009 1773 1783
90. M.C. Ljungberg, C.N. Sunnen, J.N. Lugo, A.E. Anderson, and G. D'Arcangelo Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia Dis Model Mech 2 2009 389 398
91. C.H. Kwon, X. Zhu, J. Zhang, and S.J. Baker mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo Proc Natl Acad Sci U S A 100 2003 12923 12928
92. C.N. Sunnen, A.L. Brewster, J.N. Lugo, F. Vanegas, E. Turcios, and S. Mukhi Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice Epilepsia 52 2011 2065 2075
93. P.S. Buckmaster, E.A. Ingram, and X. Wen Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy J Neurosci 29 2009 8259 8269
94. X. Huang, H. Zhang, J. Yang, J. Wu, J. McMahon, and Y. Lin Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy Neurobiol Dis 40 2010 193 199
95. D. Zemke, S. Azhar, and A. Majid The mTOR pathway as a potential target for the development of therapies against neurological disease Drug News Perspect 20 2007 495 499
96. S. Carloni, G. Buonocore, and W. Balduini Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury Neurobiol Dis 32 2008 329 339
97. S. Erlich, A. Alexandrovich, E. Shohami, and R. Pinkas-Kramarski Rapamycin is a neuroprotective treatment for traumatic brain injury Neurobiol Dis 26 2007 86 93
98. J.D. Frost Jr., and R.A. Hrachovy Pathogenesis of infantile spasms: a model based on developmental desynchronization J Clin Neurophysiol 22 2005 25 36
99. P.B. Crino Focal brain malformations: seizures, signaling, sequencing Epilepsia 50 Suppl. 9 2009 3 8
100. A. Schonberger, P. Niehusmann, H. Urbach, M. Majores, A. Grote, and H. Holthausen Increased frequency of distinct TSC2 allelic variants in focal cortical dysplasias with balloon cells and mineralization Neuropathology 29 2009 559 565
101. R. Bombardieri, M. Pinci, R. Moavero, C. Cerminara, and P. Curatolo Early control of seizures improves long-term outcome in children with tuberous sclerosis complex Eur J Paediatr Neurol 14 2010 146 149
102. C.J. Chu-Shore, P. Major, S. Camposano, D. Muzykewicz, and E.A. Thiele The natural history of epilepsy in tuberous sclerosis complex Epilepsia 51 2010 1236 1241
103. J.P. Osborne, A.L. Lux, S.W. Edwards, E. Hancock, A.L. Johnson, and C.R. Kennedy The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification Epilepsia 51 2010 2168 2174
104. J.H. Cross Neurocutaneous syndromes and epilepsy - issues in diagnosis and management Epilepsia 46 Suppl. 10 2005 17 23
105. H. Bastos, P.F. da Silva, M.A. de Albuquerque, A. Mattos, R.S. Riesgo, and L. Ohlweiler Proteus syndrome associated with hemimegalencephaly and Ohtahara syndrome: report of two cases Seizure 17 2008 378 382
106. T. Chachua, M.S. Yum, J. Veliskova, and L. Velisek Validation of the rat model of cryptogenic infantile spasms Epilepsia 52 2011 1666 1677
107. M.H. Scantlebury, A.S. Galanopoulou, L. Chudomelova, E. Raffo, D. Betancourth, and S.L. Moshe A model of symptomatic infantile spasms syndrome Neurobiol Dis 37 2010 604 612
108. L.H. Zeng, S. McDaniel, N.R. Rensing, and M. Wong Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword? Cell Cycle 9 2010 2281 2285
109. L.L. Chen, H.F. Feng, X.X. Mao, Q. Ye, and L.H. Zeng One hour of pilocarpine-induced status epilepticus is sufficient to develop chronic epilepsy in mice, and is associated with mossy fiber sprouting but not neuronal death Neurosci Bull 29 2013 295 302
110. A.L. Brewster, J.N. Lugo, V.V. Patil, W.L. Lee, Y. Qian, and F. Vanegas Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage PLoS One 8 2013 e57808
111. P.S. Buckmaster, and F.H. Lew Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy J Neurosci 31 2011 2337 2347
112. A. Sliwa, G. Plucinska, J. Bednarczyk, and K. Lukasiuk Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy Neurosci Lett 509 2012 105 109
113. J. Park, J. Zhang, J. Qiu, X. Zhu, A. Degterev, and E.H. Lo Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice J Cereb Blood Flow Metab 32 2012 330 340
114. S. Carloni, S. Girelli, C. Scopa, G. Buonocore, M. Longini, and W. Balduini Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia Autophagy 6 2010 366 377
115. R. Sankar, S. Auvin, Y.S. Kwon, E. Pineda, D. Shin, and A. Mazarati Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling Epilepsia 51 Suppl. 3 2010 39 42
116. D.H. Lowenstein Epilepsy after head injury: an overview Epilepsia 50 Suppl. 2 2009 4 9
117. L.Z. Sha, X.L. Xing, D. Zhang, Y. Yao, W.C. Dou, and L.R. Jin Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy PLoS One 7 2012 e39152
118. E. Russo, R. Citraro, G. Donato, C. Camastra, R. Iuliano, and S. Cuzzocrea mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy Neuropharmacology 69 2013 25 36
119. +/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors J Transl Med 8 2010 14
120. V.M. Rivera, R.M. Squillace, D. Miller, L. Berk, S.D. Wardwell, and Y. Ning Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens Mol Cancer Ther 10 2011 1059 1071
121. S.W. Way, J. McKenna III, U. Mietzsch, R.M. Reith, H.C. Wu, and M.J. Gambello Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse Hum Mol Genet 18 2009 1252 1265
122. L. Meikle, D.M. Talos, H. Onda, K. Pollizzi, A. Rotenberg, and M. Sahin A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival J Neurosci 27 2007 5546 5558
123. C. Fu, B. Cawthon, W. Clinkscales, A. Bruce, P. Winzenburger, and K.C. Ess GABAergic interneuron development and function is modulated by the Tsc1 gene Cereb Cortex 22 2012 2111 2119
124. R. Waltereit, H. Welzl, J. Dichgans, H.P. Lipp, W.J. Schmidt, and M. Weller Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis J Neurochem 96 2006 407 413
125. C. von der Brelie, R. Waltereit, L. Zhang, H. Beck, and T. Kirschstein Impaired synaptic plasticity in a rat model of tuberous sclerosis Eur J Neurosci 23 2006 686 692
126. P. Curatolo, S. Seri, M. Verdecchia, and R. Bombardieri Infantile spasms in tuberous sclerosis complex Brain Dev 23 2001 502 507
127. P.B. Crino mTOR: a pathogenic signaling pathway in developmental brain malformations Trends Mol Med 17 2011 734 742
128. R. Pilarski, J.A. Stephens, R. Noss, J.L. Fisher, and T.W. Prior Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features J Med Genet 48 2011 505 512
129. E.G. Puffenberger, K.A. Strauss, K.E. Ramsey, D.W. Craig, D.A. Stephan, and D.L. Robinson Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5 Brain 130 2007 1929 1941
130. K.A. Orlova, W.E. Parker, G.G. Heuer, V. Tsai, J. Yoon, and M. Baybis STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice J Clin Invest 120 2010 1591 1602
131. J.D. Feldman, L. Vician, M. Crispino, G. Tocco, M. Baudry, and H.R. Herschman Seizure activity induces PIM-1 expression in brain J Neurosci Res 53 1998 502 509
132. Y.K. Kim, J. Suarez, Y. Hu, P.M. McDonough, C. Boer, and D.J. Dix Deletion of the inducible 70-kDa heat shock protein genes in mice impairs cardiac contractile function and calcium handling associated with hypertrophy Circulation 113 2006 2589 2597
133. D.T. Balu, G.C. Carlson, K. Talbot, H. Kazi, T.E. Hill-Smith, and R.M. Easton Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function Hippocampus 22 2012 230 240
134. H. Cho, J. Mu, J.K. Kim, J.L. Thorvaldsen, Q. Chu, and E.B. Crenshaw III Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science 292 2001 1728 1731
135. R.M. Easton, H. Cho, K. Roovers, D.W. Shineman, M. Mizrahi, and M.S. Forman Role for Akt3/protein kinase Bgamma in attainment of normal brain size Mol Cell Biol 25 2005 1869 1878
136. S. Tokuda, C.L. Mahaffey, B. Monks, C.R. Faulkner, M.J. Birnbaum, and S.C. Danzer A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice Hum Mol Genet 20 2011 988 999
137. C.R. Houser, C.S. Huang, and Z. Peng Dynamic seizure-related changes in extracellular signal-regulated kinase activation in a mouse model of temporal lobe epilepsy Neuroscience 156 2008 222 237
138. J.N. Lugo, L.F. Barnwell, Y. Ren, W.L. Lee, L.D. Johnston, and R. Kim Altered phosphorylation and localization of the A-type channel, Kv4.2 in status epilepticus J Neurochem 106 2008 1929 1940
139. V. Tsai, W.E. Parker, K.A. Orlova, M. Baybis, A.W. Chi, and B.D. Berg Fetal brain mTOR signaling activation in tuberous sclerosis complex Cereb Cortex 2013 10.1093/cercor/bhs310 (in press)
140. L.H. Zeng, N.R. Rensing, and M. Wong Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mTOR) pathway Mol Cell Pharmacol 1 2009 124 129
141. H. Tang, H. Long, C. Zeng, Y. Li, F. Bi, and J. Wang Rapamycin suppresses the recurrent excitatory circuits of dentate gyrus in a mouse model of temporal lobe epilepsy Biochem Biophys Res Commun 420 2012 199 204
142. D.M. Talos, H. Sun, X. Zhou, E.C. Fitzgerald, M.C. Jackson, and P.M. Klein The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway PLoS One 7 2012 e35885